FindTrial
Sign In

Long Term Follow-up (LTFU) study 16-20 yrs after vaccine dose of hepatitis b with/without Hepatitis B immunoglobulin (HBIG) in newborns to Hepatitis B envelope antigen positive (HBeAg+) mothers.

Comparative study of the immunogenicity and protective efficacy of GlaxoSmithKline Biologicals’ rec-DNA Hepatitis B vaccine (10µg) with or without Hepatitis B immunoglobulin (HBIG) in newborns of Hepatitis B envelope antigen positive (HBeAg+) mothers - HBV-302 EXT:HBV-143 Y15-Y20

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-004879-36-Outside-EU/EEA
Enrollment
69
Registered
2015-05-22
Start date
Unknown
Completion date
Unknown
Last updated
2015-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaccination of healthy newborns of HBsAg+ and/or HBeAg+ mothers against Hepatitis.

Interventions

Trade Name: Engerix™-B Junior Product Name: Engerix™-B Junior Product Code: HBV Paediatric 10 Pharmaceutical Form: Suspension for injection INN or Proposed INN: - Current Sponsor code: HBsAg Other des

Sponsors

GlaxoSmithKline Biologicals
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Subjects who participated in the primary study and were interested in participating in a follow-up study. Written informed consent was obtained from the subjects or subject’s parents/LAR at each of the annual time-points. Are the trial subjects under 18? yes Number of subjects for this age range: 30 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 39 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

MeasureTime frame
Main Objective: To evaluate the anti-Hepatitis Bs persistence up to Year 20 after the first vaccine dose of the primary vaccination. To evaluate the prevalence and incidence of other Hepatitis B markers (Hepatitis B surface antigen [HBsAg], antibodies to Hepatitis B core antigen [anti-HBc], HBeAg, antibodies to Hepatitis B envelope antigen [anti-HBe] ) up to Year 20 after the first vaccine dose of the primary vaccination. To evaluate the clinical significance of the HBsAg positive and anti-HBc positive cases observed during the long-term follow-up of this study. ;Secondary Objective: Not applicable;Primary end point(s): The anti-HBs surface seropositivity rate, seroprotection rate and Geometric Mean Titre (GMT). The prevalence and incidence of other Hepatitis B markers (HBsAg, anti-HBc, HBeAg, anti-HBe). A case by case review of the clinical significance of the HBsAg positive and anti-HBc positive cases observed during the long-term follow-up of this study.;Timepoint(s) of evaluation of this end point: At Years 15, 16, 17, 18, 19 and 20.—

Secondary

MeasureTime frame
Secondary end point(s): Not Applicable;Timepoint(s) of evaluation of this end point: Not applicable—

Countries

Thailand

Contacts

Public ContactClinical Disclosure Advisor

GlaxoSmithKline Biologicals

GSKClinicalSupportHD@gsk.com442089904466

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026